Related Experiment Videos

Treatment of paediatric non-cystic fibrosis bronchiectasis

Elizabeth Anne Edwards1, Jacob Twiss, Catherine Ann Byrnes

  • 1University of Auckland and Starship Children's Hospital, Department of Respiratory Medicine, Private Bag 92024, Auckland, New Zealand. LizE@adhb.govt.nz

Expert Opinion on Pharmacotherapy
|June 24, 2004
PubMed

Insights

Non-cystic fibrosis bronchiectasis, an airway dilatation condition, significantly impacts respiratory health. This review examines current treatments and future therapies for this often-overlooked respiratory disease.

Area of Science:

  • Pulmonology
  • Respiratory Medicine

Background:

  • Non-cystic fibrosis bronchiectasis is a chronic respiratory condition characterized by abnormal bronchial airway dilation.
  • It results from diverse lung insults, leading to significant morbidity and mortality.
  • While often considered uncommon in developed nations, its impact on specific populations is gaining attention.

Purpose of the Study:

  • To review current evidence-based treatment practices for non-cystic fibrosis bronchiectasis.
  • To provide expert opinion on best practice management strategies.
  • To discuss emerging therapies and pharmacoeconomic challenges.

Main Methods:

  • Comprehensive literature review of existing evidence on bronchiectasis management.
  • Synthesis of current treatment guidelines and clinical trial data.
  • Expert opinion and discussion of future therapeutic directions.

Main Results:

  • Limited data currently exists to guide management strategies effectively.
  • Current treatments focus on airway clearance, infection control, and anti-inflammatory approaches.
  • Newer therapies targeting underlying mechanisms are under investigation.

Conclusions:

  • Effective management of non-cystic fibrosis bronchiectasis requires a multifaceted approach.
  • Further research is needed to establish optimal treatment protocols and address pharmacoeconomic barriers.
  • Future therapies hold promise for improving outcomes in affected populations.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chest Physiotherapy01:24

Chest Physiotherapy

Chest Physiotherapy (CPT) is a therapeutic technique used in respiratory care to improve ventilation, clear bronchial secretions, and enhance the efficiency of respiratory muscles. This therapy includes three primary procedures: postural drainage, percussion, and vibration. It can be performed on spontaneously breathing patients and those who are intubated and mechanically ventilated.
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...